Head-to-head evidence
ALLO-715 vs BCMA CAR-NK (Hrain)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: BCMA · full Multiple Myeloma pipeline
ALLO-715
Developed by Allogene Therapeutics, Inc.
NCT04093596 · Phase 1 · completed
Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
BCMA CAR-NK (Hrain)
Developed by Hrain Biotechnology Co., Ltd.
NCT05008536 · Phase 1 · status unknown
This was an open-label, single-arm study with no randomization, no blinding, and no comparator arm, in only 27 participants. Results have not been posted yet. (Independently confirmed by a second model, in-session-confirm:claude-opus-20260822.)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ALLO-715's landscape · BCMA CAR-NK (Hrain)'s landscape